J&J forecasts $2.5B COVID vaccine sales this year, lagging rivals
NY Post
Pharmaceutical giant Johnson & Johnson revealed Wednesday that it expects to take home about $2.5 billion from COVID-19 vaccine sales in 2021, far lower than estimates from its jab rivals Moderna and Pfizer.
Pfizer and Moderna have previously forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively. Those two-shot vaccines were approved by US regulators last year, while J&J’s one-shot vaccine was approved earlier this year. J&J’s vaccine has been hit by various setbacks, including concerns over rare but severe side effects that appear to be linked to the vaccine as well as questions over the shot’s effectiveness against new variants of the virus.More Related News
Gilgo Beach murder suspect Rex Heuermann was charged Thursday morning with the murders of two additional women after it was revealed that a series of disturbing “planning documents” were discovered on a hard drive in his home — with the alleged killer nodding as prosecutors read in court the twisted instructions, which included to hit the victim “harder next time”